Nintib 100 mg and 150 mg tablets are generic formulations of Nintedanib, developed and marketed by Cipla Ltd. These medications fall under the pharmacological category of tyrosine kinase inhibitors, specifically targeting multiple kinases involved in the processes of fibrosis and angiogenesis. Nintedanib is classified under the ATC code L01EX09, indicating its use in cancer therapy.
Category | Tyrosine kinase inhibitors |
Brand | Cipla |
Ingredient | Nintedanib |
Prescription Required | Yes |
Strength | 100/150mg |
Package | 10 Tablets |
Nintib 100 mg and 150 mg, both containing the active ingredient Nintedanib, work by inhibiting a group of enzymes known as tyrosine kinases that are involved in the development of fibrosis (scarring) and the formation of new blood vessels (angiogenesis). These enzymes play a critical role in signaling pathways that contribute to the progression of conditions like idiopathic pulmonary fibrosis (IPF) and non-small cell lung cancer (NSCLC). By blocking these pathways, Nintib helps to slow down the build-up of scar tissue in the lungs, thereby preserving lung function and improving breathing in patients with fibrotic lung diseases.
Nintib 100 mg and 150 mg offer significant benefits for patients suffering from progressive fibrotic lung diseases and certain types of lung cancer. In patients with idiopathic pulmonary fibrosis (IPF) and other chronic interstitial lung diseases, Nintib helps slow the progression of lung scarring, which can preserve lung capacity and improve daily functioning and quality of life. It is also beneficial in systemic sclerosis-associated interstitial lung disease (SSc-ILD), where it helps reduce the rate of lung function decline.
The most common side effects of Nintib 100 and 150mg are
• Diarrhea
• Nausea
• Vomiting
• Abdominal pain
• Loss of appetite
• Weight loss
• Headache
• Fatigue
• Elevated liver enzymes (seen in blood tests)
• High blood pressure (hypertension)
Other side effects of Nintib 100 and 150mg can include
• Liver toxicity (e.g., jaundice, dark urine, elevated liver enzymes)
• Bleeding complications (e.g., nosebleeds, gastrointestinal bleeding)
• Gastrointestinal perforation (rare but serious)
• Thromboembolic events (e.g., deep vein thrombosis, stroke, heart attack)
• Skin rashes or itching
• Dehydration (due to prolonged diarrhea or vomiting)
• Dizziness
• Joint or muscle pain
• Increased risk of infection
• Poor wound healing (especially post-surgery)
Nintib 100 mg and 150 mg (Nintedanib) should not be taken by individuals who have a known allergy to Nintedanib or any of the ingredients in the medication, as this could cause severe allergic reactions. It is also contraindicated during pregnancy due to its potential to harm the developing fetus, and it should be avoided during breastfeeding as it is not known whether the drug passes into breast milk. People with severe liver disease or liver impairment should not use Nintib, as it is metabolized in the liver, and taking it could worsen liver function.
Nintib 100 mg and 150 mg should be taken exactly as prescribed by your healthcare provider, typically twice a day, around 12 hours apart. It is important to take the tablets with food to help reduce the risk of gastrointestinal side effects, such as nausea and diarrhea. The tablets should be swallowed whole with a glass of water—do not crush, chew, or open them, as this can interfere with the medication’s effectiveness.
There are no reviews yet.